Background: The aim of the study was to evaluate the cir-
Introduction
Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are a group of slow-growing tumors which can be cured surgically in most patients (1) . There is little data regarding the inflammation processes associated with this disease. We have recently demonstrated that serum tumor necrosis factor receptor-1 is elevated in patients with IPMNs and in those with pancreatic adenocarcinomas, suggesting high apoptotic activity in both groups of patients studied (2) . Among the causes of the aggressive behavior of ductal exocrine pancreatic tumors, angiogenesis appears to be essential for tumor growth and the development of metastases and angiogenetic factors, such as vascular endothelial growth factor (VEGF), which seem to play a pivotal role (3) . VEGF specifically interacts with receptor tyrosine kinases, such as vascular endothelial growth factor receptor-2 (VEGFR-2), which are mainly expressed by endothelial cells, but also by some cancer cells, and they seem to be responsible for the poor prognosis of various tumors (4) . Furthermore, vascular endothelial growth factor-D (VEGF-D) is one of the major factors associated with the growth of lymphatic endothelial cells (5) . Finally, endostatin is a potent inhibitor of angiogenesis, and increased concentrations of this protein may be associated with cancer progression (6) . Thus, several active and passive strategies appear to be adopted by tumor cells to determine the spread of the tumor from the primary site.
All these substances have been studied in pancreatic ductal adenocarcinoma, mainly in pathological specimens, but not in patients with pancreatic IPMNs. Thus, the main aim of the present study was to evaluate the circulating concentrations of VEGF, VEGF-D, VEGFR-2 and endostatin in malignant diseases of the pancreas, such as IPMNs and pancreatic adenocarcinomas. We also evaluated the concentrations of these molecules in comparison to CA 19-9. (7), and pancreatic insufficiency was defined as a fecal elastase-1 concentration of -200 mg/g (8) . At the time of the study, none of the patients had had any treatment for their disease. Of the 31 patients with IPMNs, 16 (51.6%) had branch type IPMNs and the remaining 15 (48.4%) had main duct type IPMNs.
As shown in Table 1 , the two groups of patients were not statistically different regarding gender (ps1.000), age (ps0.594) and localization of the tumor (ps0.166) whereas the BMI of the patients with pancreatic ductal adenocarcinoma was significantly lower than that of patients having an IPMN (p-0.025). In addition, the frequency of metastases (p-0.001), pain (p-0.001), jaundice (ps0.002) and diabetes (p-0.001) were significantly higher in patients with pancreatic ductal adenocarcinoma than in those having IPMNs. The frequency of pancreatic exocrine insufficiency at the time of the study, and the frequency of patients who underwent pancreatic surgery after the diagnosis, were not different between the groups of patients studied (ps1.000 and ps0.108, respectively).
Finally, 30 blood donors were also studied as healthy controls (17 males, 13 females; mean age 59.7"8.1; ps0.825 and p-0.001 vs. the gender and the age of patients, respectively).
Methods
Fasting blood specimens were obtained in the morning from each subject enrolled. Laboratory personnel were unaware of the clinical diagnoses or the details of the patients' clinical histories. Serum was stored at -208C until analysis.
Concentrations of VEGF, VEGF-D, VEGFR-2, and endostatin were determined using enzyme-linked immunosorbent assays (ELI-SA) (R&D System, Minneapolis, MN, USA). This analysis employs a quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for this molecule was pre-coated onto a microplate. After dilution, standards and samples were pipetted into the wells. After washing away any unbound substances, an enzymelinked monoclonal antibody specific for each of these molecules was added to the wells. After removing any unbound antibodyenzyme reagent, substrate solution was added to the wells and color developed in proportion to the amount of our specific molecules.
The reaction was stopped with 50 mL HCl and the intensity of the color was measured at 450 nm. The dilution factor was recorded in order to calculate the concentration of VEGF, VEGF-D, VEGFR-2 and endostatin in the samples.
The maximum intra-and inter-assay coefficients of variation (CVs) were 5.44% and 7.30% for VEGF (20 determinations at each .57% for endostatin (20 determination at each concentration of 10, 50 and 100 ng/mL), respectively. The detection limits were 9 pg/ mL for VEGF, 11.4 pg/mL for VEGF-D, 7 pg/mL for VEGFR-2, and 0.023 ng/mL for endostatin. Finally, we also assayed CA 19-9 using an electrochemical luminescence immunoassay (CA 19-9, Roche, Milan, Italy; reference limits 0-37 U/mL).
Ethics
The study was approved by the Clinical Committee of the Department of Internal Medicine of Sant'Orsola Hospital of Bologna (Italy) and was performed in accordance with the Helsinki Declaration of the World Medical Association. All subjects gave written informed consent to participate in the study.
Statistical analysis
Means, standard deviations (SD), and frequencies were used as descriptive statistics. Data were analyzed by means of non-parametric tests: the Kruskal-Wallis test, the Fisher's exact test, the Pearson x 2 , and the linear-by-linear association x 2 . The forward multivariate linear regression was used in order to identify the clinical variables independently related to the various analytes studied. Receiver operating characteristic (ROC) curve analysis was used to differentiate patients with pancreatic adenocarcinomas from those with pancreatic IPMNs. The best cut-off values were chosen to be the values of the assays which maximized the likelihood ratio (LR) obtained using the following formula: LRs(Probability of true positiveqProbability of true negative)/(Probability of false positiveqProbability of false negative) (9) . The SPSS (SPSS Inc., Chicago, IL, USA, Version 13.0) statistical package was used to analyze the data. Two-tailed p-values of -0.05 were considered statistically significant.
Results
The mean"SD values of VEGF, VEGF-D, VEGFR-2, endostatin and CA 19-9 in the three groups of patients studied are reported in Table 2 .
Serum concentrations of VEGF, VEGF-D, VEGFR-2 and CA 19-9 were significantly higher both in patients with pancreatic ductal adenocarcinoma and in those with IPMN compared with healthy subjects, while endostatin was significantly higher in pancreatic ductal adenocarcinoma patients only compared with healthy subjects. Within the group of patients, VEGFR-2 and CA 19-9 were significantly higher in patients with pancreatic ductal adenocarcinoma than in those with IPMN, while no significant differences were observed for VEGF, VEGF-D and endostatin. For this reason, we calculated the best cut-off vales for both VEGFR-2 and CA 19-9 in order to differentiate patients with pancreatic ductal adenocarcinoma from those with IPMN. As reported in Table 3 , the area under the curve (AUC) and the standard error of AUC (SE) for VEGFR-2 and CA 19-9 were 0.707"0.067 and 0.727"0.070, respectively. Using a cutoff range of 4003-4034 pg/mL for VEGFR-2, the sensitivity and the specificity of this chemokine in differentiating patients with pancreatic adenocarcinoma from those with IPMN was 86.2% and 54.8%, respectively, while, at a cutoff range of 63-89 U/mL, CA 19-9 had a sensitivity of 72.4% and a specificity of 74.2%. Regarding the clinical variables, the 23 patients with metastasis (two patients with IPMN and 21 patients with pancreatic adenocarcinoma) had serum concentrations of VEGFR-2, endostatin and CA 19-9 that were significantly higher (VEGFR-2: 5107"1216 pg/mL, ps0.012; endostatin: 131.0"98.2 ng/mL, ps0.046; CA 19-9: 2163"4852 U/mL, ps0.015) than the 37 patients without metastasis (VEGFR-2: 4302"810 pg/mL, ps0.012; endostatin: 86.1" 78.2 ng/mL, CA 19-9: 251"492 U/mL), whereas the 35 patients with diabetes (11 patients with IPMN and 24 patients with pancreatic adenocarcinoma) had serum concentrations of endostatin and CA 19-9 significantly higher (endostatin: 125.1"100.3 ng/mL, ps0.031; CA 19-9: 1557" 4017 U/mL, ps0.007) than the 25 patients without diabetes (endostatin: 72.8"57.2 ng/mL, CA 19-9: 181"296 U/mL). In addition, CA 19-9 was significantly higher in the 35 patients (eight patients with IPMN and 27 patients with pancreatic adenocarcinoma) with pain (1019"2265 U/mL) vs. the 25 patients without pain (934"4102 U/mL, ps0.026).
Multivariate analysis showed that the type of the tumor (IPMN or pancreatic adenocarcinoma) only was significantly related to VEGFR-2 serum concentrations (ps0.002). Also, the presence of diabetes only was significantly related to endostatin serum concentrations (ps0.022). In contrast, no clinical variables entered the analyses for VEGF, VEGF-D. In contrast, the presence of metastases (ps0.002) and jaundice (ps0.024) were independently and significantly related to CA 19-9 serum concentrations.
Finally, within the group of 31 patients with IPMN, no significant differences in serum concentrations of VEGF, VEGF-D, VEGFR-2, and endostatin were found between the 15 patients with main duct type IPMN and the 16 patients with branch type IPMN (Table 4) .
Discussion
Patients with pancreatic adenocarcinoma have a poor outcome, while those with IPMN of the pancreas have slow growing neoplasms which can be cured surgically in most patients (1) . The differences between the two neoplasms are also confirmed by the clinical data of our study. In fact, patients with ductal adenocarcinoma had a frequency of pain, diabetes, jaundice and metastases significantly higher than those with IPMN, as well as having significantly lower BMI. At present, there are no data regarding the angiogenetic factors released by pancreatic IPMNs. Thus, we performed the present study in order to evaluate VEGF, VEGF-D, VEGFR-2 and endostatin in patients with malignant chronic diseases of the pancreas, such as pancreatic adenocarcinoma and IPMN, because a better understanding of the circulating concentrations of angiogenetic and antiangiogenetic factors would be helpful in developing immunotherapeutic approaches to pancreatic neoplasms (10) since there is a lack of conventional immune therapeutic options for these patients, especially for those having IPMN.
For the first time, we comparatively evaluated serum concentrations of angiogenetic and antiangiogenetic factors in patients with pancreatic ductal adenocarcinoma and in patients with pancreatic IPMN. We found that serum concentrations of VEGF, VEGF-D, VEGFR-2 and endostatin were significantly higher in patients with ductal adenocarcinoma than in healthy subjects, and these results are similar to those previously reported for VEGF (3) and endostatin alone (6) . Furthermore, data on VEGF-D and VEGFR-2 have previously been reported only on pancreatic tissue and we now report these data for blood. Tumor angiogenesis is often the consequence of an angiogenetic imbalance in which proangiogenetic factors predominate over antiangiogenetic factors (11) . The fact that we found that all the circulating angiogenetic factors are increased seems to support the hypothesis that there is an inappropriate response to tumor invasiveness by the host. This is also supported by the fact that VEGFR-2, which is a marker of poor prognosis in various tumors including pancreatic cancer (4, 6), shows high serum concentrations in patients with pancreatic ductal adenocarcinoma rather than in those with IPMNs. This is also supported by the finding that patients with advanced cancer, i.e., those with metastasis and those with diabetes, had high serum concentrations of this protein. Multivariate analysis showed the type of tumor (IPMN or pancreatic adenocarcinoma) was the only clinical variable independently related to VEGFR-2 serum concentrations. However, in clinical practice, VEGFR-2 cannot be utilized as a marker to distinguish patients with pancreatic ductal adenocarcinomas from those with IPMN, because even if the sensitivity was 86.2%, the specificity was quite low (54.8%).
Also, of interest, is the fact that considering only patients with IPMN, those patients having main duct type had similar values of both proangiogenetic and antiangiogenetic factors compared with patients with branch type IPMN.
Regarding CA 19-9, this marker is also not useful for differentiating patients with pancreatic ductal adenocarcinoma from those with IPMN because the sensitivity and specificity were quite low at 72.4% and 74.2%, respectively. Our data confirm previous studies suggesting that CA 19-9 determination is not recommended for use as a screening test for pancreatic neoplasia (12, 13) and, in particular, the multivariate analysis demonstrates that the presence of metastases and jaundice were independently related to CA 19-9 serum concentrations.
In conclusion, our data further suggest that an IPMN is one of the precursors of ductal adenocarcinoma, and it has a pattern of angiogenetic factors different from ductal adenocarcinoma. However, these markers, such as CA 19-9, cannot be utilized to routinely differentiate IPMNs from pancreatic ductal adenocarcinomas.
